Trial Profile
A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics of Once-Daily Oral E5501 Tablets Used Up to 7 Days in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2018
Price :
$35
*
At a glance
- Drugs Avatrombopag (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 15 Jun 2018 Results of pooled data from 14 trials, were published in the Journal of Clinical Pharmacology.
- 18 Sep 2014 New trial record